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ABSTRACT 
Objective: This present study aims to screen pharmaceutical cocrystal of Fenofibrate and coformers. Further the preparation and evaluation of  
fenofibrate-coformer cocrystal and In-Vitro drug release and Ex-Vivo Permeation study was done. Material and Methods: The coformers for 
Fenofibrate were screened using molecular docking. The cocrystals produced were characterized using Differential Scanning Calorimetry 
(DSC), X-ray diffraction (XRPD) study and Infrared spectroscopy. Results: Cocrystal of Fenofibrate with tartaric acid was successfully prepared. 
The cocrystals displayed enhanced dissolution rate by 2.36 fold, similarly the ex-vivo drug uptake through everted chicken intestine model was 
improved by 4.38 fold. The formation of cocrystals of fenofibrate with tartaric acid was evaluated by DSC, IR and XRPD. 
Conclusion: The fenofibrate - tartaric acid cocrystal exhibited increased % drug release and permeation compared to fenofibrate. This study 
confirms that selection of proper coformer is very vital step in preparation of stable, superior cocrystal. Based upon above study and results it 
revealed that cocrystallization offers a valuable way to improve the physicochemical properties of the API.  
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INTRODUCTION 
Pharmaceutical cocrystallization is a reliable method to 
modify and improve physical and chemical properties of 
drugs such as solubility, stability, dissolution rate, 
hygroscopicity and compressibility without changing their 
pharmacological activity.1 Pharmaceutical cocrystals offer an 
alternative to chemical modification of the drug substance as 
well as established salt, solvate, amorphous, inclusion 
complexes and polymorphic drug forms all of which have 
restrictions in their utility. Formation of cocrystal depends 
on the functional groups between API and coformer, to allow 
for the occurrence of hydrogen bonds or other forms of solid 
interaction.2 Cocrystals consist of two or more neutral 
molecular components in a crystal lattice with defined 
stoichiometry. These are homogeneous phases, which are 
solids at room temperature and are held together by weak 
interactions, mainly hydrogen bonding.  
Capability of forming non-covalent interactions especially 
hydrogen bonds with an APIs forms the basis of coformer 
selection. Various approaches to coformer selection were 
supramolecular synthon approach, Hansen solubility 
parameter, pKa based, lattice energy calculation, hydrogen 
bond propensity and Molecular docking.3 
Fenofibrate is a extensively used as hypolipidemic drug. This 
drug is used mostly in lipid regulation as it decreases low-
density lipoprotein (LDL) and very-low density lipoprotein 
(VLDL) levels, and increases high density lipoprotein (HDL) 
level. Solubility and permeability are the fundamental 
parameters controlling the rate and extent of drug 
absorption. Fenofibrate is a BCS class II drug with low 
solubility and high permeability.   Various reported methods 
to improve dissolution of fenofibrate are micronization, 
nanonization, salt formation, incorporation of surface active 
agent, solid dispersion, polymorphism and cocyrstal 
synthesis. 4,5,6,7        
  The aim of the study was to improve dissolution of 
Fenofibrate using cocrystal formation. The study involved in 
silico screening of coformers, preparation and in-vitro, ex-
vivo evaluation of Fenofibrate cocrystals. The anti-solvent 
addition method was used to form cocrystals with tartaric 
acid. The cocrystals were characterized by IR spectroscopy, 
DSC and XRPD.  
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MATERIALS AND METHODS 
Materials 
Fenofibrate was provided by Medley pharmaceutical Ltd. 
Coformers catechol, tartaric acid, anthranillic acid and 
ferullic acid were purchased from LOBA CHEMIE PVT LTD. 
All required solvents and excipients  were provided by LOBA 
CHEMIE PVT LTD . Molecular docking study was performed 
using Schrodinger suite version 9.0 software.  
Methods 
Selection of coformers  
Molecular Docking 
The coformers were initially selected based upon 
supramolecular synthon approach that depicts possibility of 
hydrogen bond formation with fenofibrate1.The structures of 
four coformers; catechol (Chem Spider ID: 13837760), 
tartaric acid (Chem Spider ID:852), anthranillic acid (Chem 
Spider ID:222) and ferulic acid (Chem Spider ID: 393368) 
were retrieved from chemspider database . 
Coformer structures were prepared by LigPrep 2.3 module 
of Schrodinger suite 8. The structure of fenofibrate was 
prepared using protein preparation wizard of Maestro 9. The 
protrin structure was optimized and minimized using OPLS-
2005 force field. Molecular docking was performed using 
Glide docking program 10. The results were run on the basis 
of glide score. 
Preparation of fenofibrate cocrystals: 
1) Antisolvent addition method 1,3 
Fenofibrate and coformer weigh in 1:1 molar ratios were 
dissolved in 25 ml ethanol using moderate stirring. The 
solution was then filtered through a Whatman filter paper to 
remove any undissolved material. Distilled water was then 
added dropwise to the above solution with constant stirring 
to induce cocrystal precipitation. The cocrystals were 
allowed to dry overnight in desiccators. 
Evaluation of Cocrystal formation : 
The prepared cocrystal in present study was primarily 
confirmed by comparing DSC results, IR results and XRD 
study of cocrystals with fenofibrate (pure drug) with 
selected coformers. In vitro dissolution and ex-vivo 
permeation studies were carried out. 
Standard Calibration Curve of Fenofibrate 
Standard calibration curve of fenofibrate was developed by 
suitably diluting methanolic stock solution of fenofibrate in 
0.5% SLS solution in distilled water to obtain concentrations 
between 2 to 10μg/ml. The absorbance of resulting solutions 
was measured at 286 nm using double beam UV-Visible 
Spectrophotometer against 0.5 % SLS solution as blank. 
Differential Scanning Calorimetry (DSC): 
DSC was performed on Mettler-Toledo DSC 823* (Columbus) 
instrument and an empty standard aluminium pan were 
used as reference. DSC scans were recorded at heating rate 
of 10◦C/ min in temperature range 30-300◦C, DSC 
measurements were carried out on prepared fenofibrate 
cocrystal. 
X-ray diffraction (XRPD) study: 
Powder X-ray diffraction pattern of pure fenofibrate and 
fenofibrate cocrystal was investigated using powder X-ray 
diffractometer(PW 1729 X-ray Generator, Philips Ltd.). The 
X-rays were Ni filtered CuKα1 radiation with 40 KV and 30 
mA over  0-100o/2θ. 
Infrared spectroscopy: 
IR (Brucker,Germany) was used for collecting the IR 
samples. The spectra were collected over the range of 4000-
600 cm-1 in 32 scans, with resolution of 4 cm-1  for each 
sample. 
Determination of drug content: 
Drug content was determined by dissolving samples of co-
crystals equivalent  to 10 mg fenofibrate in 100 ml of 
methanol. After suitable dilution absorbance of resulting 
solutions was measured at 286 nm using double beam UV-
Visible Spectrophotometer. 
In- vitro dissolution study: 10 
  In vitro dissolution study was carried out using USP 
dissolution apparatus II.The rotation speed of the paddles 
was set to 100 rpm. About 900 mL of 0.5 % Sodium lauryl 
sulphate (SLS) at 37 ± 0.5°C was used as the dissolution 
medium. At predetermined time intervals 5 mL samples 
were withdrawn, filtered through 0.45 µm membrane 
immediately, and 5 mL blank dissolution medium was added 
for replenishing of the dissolution medium, respectively. The 
amount of dissolved drug was determined at 286 nm using a 
UV spectrophotometer. 
Ex-vivo permeation studies using everted chicken 
intestine 11 
To understand the absorption mechanism of fenofibrate and 
fenofibrate cocrystal, everted gut sac studies using chicken 
intestinal segments were performed. Intestine was washed 
carefully with Krebs ringer solution and different segments 
of small intestine were identified. A length of 8–10 cm was 
rapidly removed and gently everted over a glass rod. The 
everted intestine was then slipped off the glass rod and 
placed in a flat dish containing Krebs–Henseleit bicarbonate 
(KHB) buffer oxygenated with O2/CO2 (95%/5%) at 370C. 
The in vitro absorption system consisted of USP dissolution 
apparatus II operated at 100 rpm containing 5% SLS (900 
ml) as dissolution medium maintained at 37±0.5℃. Modified 
perfusion apparatus hol ding isolated everted intestine 
segment was placed in dissolution vessel. In this system, 
drug dissolution from formulation and permeation across 
everted intestine occurred simultaneously. 
The fenofibrate and fenofibrate cocrystals was transferred in 
separate dissolution vessels. The aliquotes were collected at 
predetermined time intervals of 5, 10, 15, 30, 45, 60 min and 
the equal volumes of dissolution and serosal fluids were 
replaced.  The samples were analyzed spectrophoto-
metrically at 286 nm. 
RESULTS AND DISCUSSION 
Molecular Docking 
The molecule of fenofibrate  structure consists of two 
aromatic rings , two carbonyl groups, ether group and 
chlorine group. Fenofibrate molecule has three hydrogen 
bond acceptors  as well as seven rotatable bond count., 
hence it can easily form co-crystals with other co-
formers(figure 1). Coformers chosen in this work were 
catchol, tartaric acid, anthranillic acid and ferullic acid . The 
result of virtual screening of conformers using molecular 
docking is shown in table 1. 
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Figure-1 Molecular structure of fenofibrate 
Glide score and hydrogen bonding parameters were used to 
determine the best possible coformer. The lowest value of 
Glide score shows the best interaction between fenofibrate 
and the coformer. The maximum hydrogen bond formation 
assists in higher binding affinity. The lowest Glide score of -
4.28 kcal/mol and highest number of hydrogen bond 
formation with fenofibrate was exhibited by tartaric acid. 
Therefore, on the basis of number of hydrogen bond and 
least glide score tartaric acid coformer was selected for 
further studies. 
  
Table 1- Virtual screening of co-formers with fenofibrate using molecular docking 
Coformer Structure Type of 
Interaction 
 
Fenofibrate 
atoms 
involved in 
binding 
Coformer 
atoms 
involved in 
binding 
Glide-
score  
Catechol 
 
1)Hydrogen 
bonding. 
2)π-π  
interaction 
 
-C=O H (-OH)  -1.38 
tartaric acid 
 
1)Hydrogen 
bonding. 
 
-C=O H (-OH)  -4.28 
anthranillic 
acid 
 
1) π-π  
interaction 
-- -- -0.14 
Ferulic acid 
 
No interaction  -- -- -- 
 
Standard Calibration Curve of fenofibrate: 
The absorption maxima of fenofibrate are reported at 286. 
nm. A linear relationship between the concentration and 
absorbance of fenofibrate were established over the 
examined concentration range (2-10 μg/mL). Calibration 
curve of fenofibrate was established. The equation of line 
was y = 0.056x + 0.027 and R² = 0.997 (figure-2) 
 
O
O
O
O
Cl
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Figure-2: Calibration curve of fenofibrate 
Differential Scanning Calorimetry (DSC) 
DSC was conducted to investigate the molecular state of 
fenofibrate into cocrystal. DSC thermograms obtained for 
fenofibrate(Figure -3 ) and Finofibrate tartaric acid cocrystal 
(Figure -4 ) showed well-defined endothermic peak  at 
81.52°C corresponding to the melting point of crystalline 
drug and prepared cocrystals showed endothermic peaks at 
83.67°C . This is due to increased crystallinity observed 
fenofibrate showed 316% crystallinity while fenofibrate 
tartaric acid cocrystal showed 560.90% Crystallinity. 
 
Figure -3: DSC thermograph of fenofibrate 
 
Figure -4: DSC thermograph of fenofibrate-tartaric acid 
cocrystal 
Infrared spectroscopy: 
The possible interaction between the drug and the coformers 
was studied by IR spectroscopy. From the results of IR, it was 
observed that all the important peaks due to functional 
groups of  fenofibrate were present, the peak at 2982.49cm -
1 indicates aromatic C-H stretching, peak at 1590cm -1 
indicates C=O stretching, whereas peaks at 1287cm -1 and 
1093cm -1 indicate aralkyl and dialkyl ether C-O stretching, 
respectively(figure-5).  Tartaric acid IR showed a 
characteristic peak OH at 3352.53 cm-1 and C=O peak at 
1708.96 cm -1. 
 However some changes in the cocrystal IR spectrum were 
observed such as presence of  peak at 1737.43 cm -1 and OH 
stretch at 3260.64 cm -1 in prepared fenofibrate cocrystals 
(figure-6) when compared to pure drug, thereby indicating 
that hydrogen bonding has occurred in the cocrystals .  
 
Figure -5:  IR fenofibrate 
 
Figure -6:  IR fenofibrate-tartaric acid cocrystal 
X-ray diffraction (XRPD) study: 
The formation of cocrystal was confirmed on the basis of 
XRPD studies which showed differences in diffractogram of 
cocrystal and fenofibrate. The diffraction pattern of cocrystal 
is completely different from fenofibrate and fenofibrate 
tartaric acid cocrystal showed characteristic diffraction 
peaks at different 2θ values (14.71, 16.52, 16.42, 22.53) 
(Figure-7)and 2θ values (12.31, 21.31, 22.73, 25.14)(Figure-
8)indicating change in crystallinity respectively. The change 
in relative intensities of their XRPD peaks attributed to 
different crystal habits and arrangement of molecules 
indicating formation of new cocrystal. 
 
Figure -7: XRD fenofibrate 
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Figure -8: XRD fenofibrate-tartaric acid cocrystal 
Drug content  
Percentage drug content of fenofibrate-tartaric acid cocrystal 
was found to be 78.67%W/W. 
In-Vitro Drug release:  
The in vitro dissolution profiles of the cocrystal were 
compared with that of pure fenofibrate (figure-9). The in 
vitro dissolution rate of cocrystal was increased compared to 
the drug. Pure drug shows 40.55% drug release after 60 min, 
whereas cocrystals show 95.8% . The high dissolution rate of 
prepared cocrystal can be attributed to change in 
crystallinity of fenofibrate due to possible hydrogen bond 
interaction with coformer. The antisolvent addition method 
produces  non-hygroscopic solid form of  fenofibrate 
cocrystal with markedly enhanced dissolution rate.  
 
Figure 9: In vitro drug release from fenofibrate pure 
drug and fenofibrate-tartaric acid cocrystal. 
Ex-vivo permeation study:  
Pure fenofibrate showed 15.98% absorption while 
Fenofibrate-tartaric acid cocrystal showed 70.1% 
absorption. Increase in the absorption might be due to the 
increase in solubility and dissolution rate. (Figure -10) 
 
Figure 10: Ex-vivo permeation studies using everted 
chicken intestine 
CONCLUSION 
The present study was aimed to investigate the use of 
Molecular docking in prediction of cocrystal formation 
between fenofibrate and coformers, and evaluate the 
prepared cocrystals by DCS, IR ,XRPD along with in-vitro 
drug release and ex-vivo permeation study of cocrystal. The 
investigated approach was effective in predicting coformer 
for fenofibrate in preparation of cocrystal.  
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